Formulary
Inotersen: Indications, Dosing, Side Effects and Interactions
Inotersen is an antisense oligonucleotide inhibitor which inhibits transthyretin production.
MedNext Academy | 3 min read
Inotersen: Indications, Dosing, Side Effects and Interactions
Inotersen is an antisense oligonucleotide inhibitor which inhibits transthyretin production.
Drug action
Inotersen is an antisense oligonucleotide inhibitor which inhibits transthyretin production.
Indications and dose
**Stage 1 or stage 2 polyneuropathy in patients with hereditary transthyretin amyloidosis (hATTR) (initiated by a specialist)**
- **Adult** (By Subcutaneous Injection): 284 mg once weekly, for dose adjustments due to side-effects and information on Vitamin A supplementation-consult product literature.
Cautions
Concomitant administration with nephrotoxic drugs; elderly; history of major bleeding
Contraindications
Patients undergoing liver transplantation (no information available); platelet count less than 100x10 9 /litre before starting treatment; urine protein to creatinine ratio (UPCR) greater than or equal to 113 mg/mmol before starting treatment
Side effects
Common or very common Anaemia; appetite decreased; chills; eosinophilia; fever; glomerulonephritis; haematoma; headache; hypotension; influenza like illness; nausea; peripheral oedema; peripheral swelling; proteinuria; renal impairment; skin reactions; thrombocytopenia; vomiting Frequency not known Intracranial haemorrhage; solid organ transplant rejection; vitamin A deficiency
Pregnancy
Manufacturer advises avoid unless essential (limited information available)-potential teratogenic risk due to unbalanced vitamin A levels, consult product literature.
Breast feeding
Manufacturer advises avoid-present in milk in animal studies.
Hepatic impairment
Manufacturer advises avoid in severe impairment (no information available).
Renal impairment
Manufacturer advises avoid if eGFR less than 45 mL/minute/1.73 m 2 . See Prescribing in renal impairment .
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Inotersen in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

